A Physicochemical and Radomized Controlled Clinical Study Of Padmaka (Prunus cerasoides D.DON) As Vedanasthapaka In Supti (NUMBNESS) W.S.R.To Diabetic Neoropathy.

A PHYSICOCHEMICAL AND RANDOMIZED CONTROLLED CLINICAL STUDY OF PADMAKA (Prunus cerasoides D. DON) AS VEDANASTHAK IN SUPTI (NUMBNESS) W.S.R.TO DIABETIC NEUROPATHY. - Nill

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087024

Enrollment

Registered

2025-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subject willing to give written informed consent.2.Patients ready to comply trial protocol. 3.Both gender with Age between 30-70 years. 4.Patients diagnosed with Type 2 diabetes mellitus with evidence of clinical, symptomatic, symmetric, distal neuropathy with numbness. 5.Patients with atleast 7-8 years of duration of diabetes

Exclusion criteria

Exclusion criteria: 1.Subjects not willing to give written informed consent. 2.Age below 30 and above 70 years 3.K/C/O of Leprosy, gangrene or where permanent nerve damage occurs. HIV, or any other debelating disorders. 4.Patients who are not ready to comply the trial protocols. 5.Those with any neuropathy other than diabetic neuropathy. 6.Patients with Peripheral vascular disease. 7.Those on antidepressants, opiates, anticonvulsant, capsaicin and also an aldose deductase inhibitors.

Design outcomes

Primary

Measure	Time frame
To study physicochemical properties and clinical efficacy of Padmak (Prunus cerasoides D. DON) as Vedanasthapak (establish densation at sensrless sight) in supti (numbness) w.s.r to diabetic neuropathy. To see effect of Padmak as Vedanasthapak in Supti w.s.r to numbness in Diabetic neuropathy. To analyse pharmacognostic and physicochemical properties of Padmak. To co-relate Supti with diabetic neuropathy. Timepoint: baseline and after every 15 days upto 3 months	—

Measure

Time frame

To study physicochemical properties and clinical efficacy of Padmak (Prunus cerasoides D. DON) as Vedanasthapak (establish densation at sensrless sight) in supti (numbness) w.s.r to diabetic neuropathy. To see effect of Padmak as Vedanasthapak in Supti w.s.r to numbness in Diabetic neuropathy. To analyse pharmacognostic and physicochemical properties of Padmak. To co-relate Supti with diabetic neuropathy. Timepoint: baseline and after every 15 days upto 3 months

—

Secondary

Measure	Time frame
â?¢ To see effect of Padmak as Vedanasthapak in Supti w.s.r to numbness in Diabetic neuropathy. Timepoint: 6 months;â?¢ To analyse pharmacognostic and physicochemical properties of Padmak.Timepoint: 1 month;â?¢To co-relate Supti with diabetic neuropathy.Timepoint: 10 days	—

Countries

India

Contacts

Public ContactDr Ashashri Tulsiram Shinde

Govt. Ayurved College, Nagpur

drsanjayleela@gmail.com9423340001

Outcome results